Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Apr

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

James P. Allison, PhD, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research

Electroacupuncture Relieves Cognitive Psychological Symptoms in Breast Cancer Survivors in Pilot Study

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy

Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients